NASDAQ:RLYP

(RLYP) (RLYP) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$31.99
$31.99
50-Day Range
N/A
52-Week Range
$10.26
$32.12
Volume
N/A
Average Volume
2.93 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RLYP stock logo

About (RLYP) Stock (NASDAQ:RLYP)

Relypsa, Inc. is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company's technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address. Its polymers are non-absorbed, meaning they act within the gastrointestinal tract and do not get absorbed into the bloodstream or other parts of the body. Its polymer technology may be able to address many health conditions in need of viable treatment options. Its VELTASSA (patiromer) for oral suspension is a commercialized medicine resulting from its polymer technology platform. VELTASSA is a potassium binder approved for the treatment of hyperkalemia. Available in powder form, VELTASSA is mixed with water and taken daily. VELTASSA's spherical beads bind to potassium in exchange for calcium, primarily in the colon.

RLYP Stock News Headlines

Ludwig Enterprises Inc LUDG
The A.I. story nobody is telling you (Read ASAP)
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
RLYP Historical Data
TECK October 20th Options Begin Trading
The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
Relypsa Fielding Takeout Offers, Shares Move Higher
See More Headlines
Receive RLYP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (RLYP) and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:RLYP
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

RLYP Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of (RLYP) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (RLYP) investors own include Royalty Pharma (RPRX), Synergy Pharmaceuticals (SGYP), Akorn (AKRX), Novavax (NVAX), Verastem (VSTM), Skechers U.S.A. (SKX), Sarepta Therapeutics (SRPT), Integrated Device Technology (IDTI) and Gilead Sciences (GILD).

This page (NASDAQ:RLYP) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners